Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

OBJECTIVES: The effects of masupirdine on the neuropsychiatric symptoms were explored. METHODS: Masupirdine (SUVN‐502) was evaluated for its effects on cognition in patients with moderate AD. The prespecified primary outcome showed no drug‐placebo difference. Post hoc analyses of domains of the 12‐i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nirogi, Ramakrishna, Jayarajan, Pradeep, Benade, Vijay, Shinde, Anil, Goyal, Vinod Kumar, Jetta, Satish, Ravula, Jyothsna, Abraham, Renny, Grandhi, Venkata Ramalingayya, Subramanian, Ramkumar, Pandey, Santosh Kumar, Badange, Rajesh Kumar, Mohammed, Abdul Rasheed, Jasti, Venkat, Ballard, Clive, Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828442/
https://www.ncbi.nlm.nih.gov/pubmed/36168659
http://dx.doi.org/10.1002/gps.5813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828442/
https://www.ncbi.nlm.nih.gov/pubmed/36168659
http://dx.doi.org/10.1002/gps.5813

Ejemplares similares